1. Introduction {#sec1}
===============

Patients with resectable esophagogastric carcinoma are commonly treated with gastrectomy and esophagectomy \[[@B1], [@B2]\]. Complications including anastomotic stenosis and/or anastomotic leakage are rare after esophagojejunostomy \[[@B3]\], with an overall incidence of less than 3.0% \[[@B4]\]. Currently, various conservative treatments have been reported, including endoscopic transluminal drainage, stent placement, and biodegradable leakage plugs, or fibrin glue \[[@B5]--[@B8]\]. Endoscopic placement of covered stents has been used for the treatment of anastomotic leakages after esophagogastrostomy or esophagojejunostomy \[[@B9], [@B10]\]. However, treating complications after esophagojejunostomy remains challenging, and the optimal protocol has not been determined \[[@B2], [@B6], [@B11]\].

To date, only limited data are available on interventional treatment of anastomotic leakage or stenosis under fluoroscopic guidance. We used an interventional protocol consisting of balloon dilation for benign anastomotic stenosis, stent for malignant, and three-tube method with or without covered esophageal stent placement for anastomotic leakage. In this study, we aimed to determine the safety and efficacy of this protocol for treatment of complications after esophagojejunostomy.

2. Methods {#sec2}
==========

2.1. Patient Selection {#sec2.1}
----------------------

This study was approved by the Ethics Committee Board of the First Affiliated Hospital of Zhengzhou University. All informed consents were obtained from the patients. This study enrolled all patients with anastomotic stenosis and/or anastomotic leakage who received interventional treatments in our department between May 2012 and February 2018. The diagnosis of complications after esophagojejunostomy was made based on finding of esophagography and the chest-computed tomography (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). Patients with esophagotracheal fistula or spontaneous esophageal perforation were excluded. All patients were treated on an inpatient basis.

2.2. Three-Tube Method {#sec2.2}
----------------------

All interventional procedures were performed under fluoroscopic guidance and conscious sedation. After the esophagus was anesthetized by oral lidocaine gel, esophagography was performed to show the site of anastomotic leakage and stenosis ([Figure 2(a)](#fig2){ref-type="fig"}). A 5 F catheter was introduced through the outlet of anastomotic leakage into the distal end of the abscess cavity ([Figure 2(b)](#fig2){ref-type="fig"}). The catheter was then exchanged with a 5 F straight or pigtail catheter (Cook Medical, Inc., Bloomington, IN). Continuous negative pressure suction was used to achieve effective drainage of abscess cavity. A gastrointestinal decompression tube and jejunal feeding tube were inserted in the intestinal cavity of the anastomosis and the proximal jejunum, respectively.

2.3. Balloon Dilation and Esophageal Stent Placement {#sec2.3}
----------------------------------------------------

Balloon dilation was performed in patient with benign anastomotic stenosis (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}). The diameter of the stents ranges from 10 to 26 mm. The length of the stents ranges from 40 to 60 mm. The retrievable covered esophageal stent was used for the treatment of anastomotic leakage or malignant stenosis, and 2 Y type of intestinal stent were used (Nanjing Micro-Tech Medical Company, Nanjing, China). The stent diameter ranges from 18 to 22 mm. The stent length ranges from 80 to 140 mm. Adequate stent coverage is allowed on both sides of the stenosis or leakage to ensure complete coverage. A 5 F catheter was introduced into the gastral cavity, and a stiff guidewire was exchanged. A stent delivery system was introduced along the stiff guidewire and then adjusted and released slowly ([Figure 2(c)](#fig2){ref-type="fig"}). Esophagography was performed again to show change of anastomotic leak and stenosis ([Figure 2(d)](#fig2){ref-type="fig"}).

2.4. Postoperative Care {#sec2.4}
-----------------------

Enteral nutrition (Milupa Gmbh & Co. KG, Friedrichsdorf, Germany) was provided through the jejunal feeding tube. Patients were not permitted to oral feed until leakage sealing and stenosis relief was confirmed by esophagography. Broad-spectrum antibiotic treatment was used for patients with anastomotic leakage before and after procedure. The abscess cavity was irrigated twice a day by physiological saline via the drainage tube. Postoperative esophagography and chest CT were performed within 1 week to show the size change of abscess cavity and the position of drainage tube (Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}; Figures [3(c)](#fig3){ref-type="fig"} and [3(d)](#fig3){ref-type="fig"}). The covered stents and drainage tubes were removed if chest CT confirmed disappearance of abscess cavity and full expansion of the lungs (Figures [1(e)](#fig1){ref-type="fig"} and [1(f)](#fig1){ref-type="fig"}; Figures [4(a)](#fig4){ref-type="fig"}--[4(d)](#fig4){ref-type="fig"}).

3. Results {#sec3}
==========

3.1. General Information {#sec3.1}
------------------------

This study involved a total of 24 patients with complications after esophagojejunostomy, including 18 men and 6 women ([Table 1](#tab1){ref-type="table"}). The ages of the patients ranged from 38 years to 74 years, with a median age of 64 years. The median disease course before referral to our department was 5.5 months (range: 0.3 to 72 months). The median interval between esophageal surgery and complications was 6.8 months (range: 0.2 to 52 months). There were 11 cases of anastomotic leakage, 11 cases of anastomotic stenosis, and 2 patients showed anastomotic leakage combined with stenosis.

3.2. Intervention Outcomes {#sec3.2}
--------------------------

Three-tube method was used for 13 patients with anastomotic leakage, of which, 7 patients received covered stent placement. For patients with anastomotic stenosis, 4 patients received balloon dilation, and 9 patients received stent placement. A total of 21 covered esophageal stents were placed for 16 patients, with a median diameter of 20 mm and median length of 100 mm. Except for failure of placement of Y-type intestinal stent in one patient due to complete occlusion, all operations were technically successful, with appropriate positions and satisfactory expansion of stents or drainage of tubes. For patients who received stent placement for anastomotic leakage, the leakage was completely blocked after stenting confirmed by immediate postprocedural esophagography. Besides, three patients received transcatheter arterial chemoembolization for cancer recurrence, one patient received lumbar sympathetic block for severe abdominal pain, and one patient received percutaneous transhepatic cholangial drainage for biliary obstruction. One colon stent was inserted, and one intestinal obstruction catheter was used for intestinal obstruction due to tumor migration.

3.3. Complications {#sec3.3}
------------------

No massive hemorrhage, esophageal rupture, or other complications occurred during procedures. Stent restenosis was found in 3 patients, and an additional stent was inserted for these patients (Figures [5(a)](#fig5){ref-type="fig"}--[5(d)](#fig5){ref-type="fig"}). Two patients showed stent migration, and stents were adjusted. No migration of abscess drainage tube was found. The abscess drainage tubes were adjusted for 0 to 6 times.

3.4. Follow-Up {#sec3.4}
--------------

Removal of stent or abscess drainage tube was successfully performed for 8 patients. The median retention time of stent was 67.5 days (range, 17 to 390 s; Figures [4(c)](#fig4){ref-type="fig"} and [4(d)](#fig4){ref-type="fig"}). The median retention time of abscess drainage tube was 87 days (range, 7 to 241 days). Except one patient lost to follow-up, 23 patients were followed up for a median time of 6.8 months (range: 0.2 to 52.0 months). At this time, 8 patients were still alive, who were able to return to their normal living conditions without any symptom. During follow-up, 14 patients died of cancer recurrence, and one died of pulmonary infection. The 1-, 3-, and 5-year survival rates were 39.5%, 23.7%, and 23.7%, respectively.

4. Discussion {#sec4}
=============

Anastomotic stenosis and anastomotic leakage are rare complications after esophagojejunostomy \[[@B3]\]. The overall incidence of anastomotic leakage and stenosis after esophagojejunostomy was 2.1%-3.0% and 2.7%-2.9%, respectively \[[@B4]\]. Management of complications after esophagojejunostomy is still challenging with no optimal treatment protocol \[[@B2], [@B6], [@B11]\]. Surgical repair was the traditional protocol \[[@B12]\], and various conservative treatment protocols have been reported, including endoscopic transluminal drainage/clipping, stent placement, biodegradable leakage plugs, or fibrin glue \[[@B5]--[@B8]\]. Esophageal stent was initially used as a palliative treatment for malignant dysphagia. Recently, esophageal stents have expanded to treat benign disease \[[@B13], [@B14]\], including plastic stents \[[@B15]--[@B17]\] and metal stents \[[@B13], [@B18], [@B19]\]. Esophageal metallic stent placement may serve as an alternative protocol for complications after esophagojejunostomy. Metallic stent has been used for treatment of malignant stenosis or perforation \[[@B18], [@B19]\], which is also used for the treatment of benign diseases in recent years, such as anastomotic leakage or stenosis \[[@B13]\]. In this study, a total of 21 covered esophageal stents were placed in 7 patients with anastomotic leakage, with a median retention time of 67.5 days.

Successful management of anastomotic leakage after esophagojejunostomy requires adequate therapy of the associated infection and effective elimination of contamination by prompt placement of the covered stent. We present 24 consecutive patients treated with interventional protocol for complications after esophagojejunostomy. We found that interventional protocol can be easily and effectively performed under fluoroscopic guidance with a high technical success rate and no severe complications. No perioperative death was observed in this study, which was lower than previous reports \[[@B15], [@B16], [@B20], [@B21]\]. The gastral cavity is still allowed to drain by a drainage tube after placement of a covered stent. The median retention time of abscess drainage tube was 87 days.

There were certain complications of the interventional protocol. Stent migration is a common complication, especially in patients without luminal stenosis \[[@B22], [@B23]\]. Covered stents were used in this study; stent migration was found in 2 patients and was adjusted effectively. Stent restenosis was found in 3 patients, and an additional stent was inserted for these patients. The drainage tube was exchanged or adjusted for 0 to 6 times.

There are some limitations in this study. This is a retrospective study with a relatively small number of patients. The healing time required for anastomotic leakage is long; however, the esophageal stents are usually removed within 3 months to avoid long-term complications.

5. Conclusions {#sec5}
==============

Our study shows that interventional treatment of complications after esophagojejunostomy can be considered a safe and effective alternative protocol. Combination of interventional treatment and additional supportive therapy is essential for anastomotic leakage.
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![Chest computed tomography for case 16. (a, b) Chest CT scan in the mediastinal and lung windows shows anastomotic leakage, atelectasis, and bilateral pleural effusion before interventional procedure. (c, d) At one month after three-tube treatment and covered stent placement, a chest CT scan shows a covered stent with decreased pleural effusion. (e, f) After removal of three-tube and covered stent, a chest CT scan shows disappearance of abscess, expansion of the lungs with no pleural effusion.](GRP2019-1465301.001){#fig1}

![A 65-year-old woman with anastomotic leakage (case 16). (a) Esophagography showing the site of anastomotic leakage in the lower esophagus. (b) A 5 F catheter was introduced through the outlet of leakage into the distal end of the abscess cavity. (c) A stent delivery system was introduced along the stiff guidewire. (d) Esophagography showed that the contrast agent flowed through the stent with no leakage after esophageal stenting.](GRP2019-1465301.002){#fig2}

![A 63-year-old man with anastomotic stenosis treated by stent placement (case 12). (a) Esophagography showed the site of anastomotic stenosis in the lower esophagus. (b) A covered stent was inserted. (c, d) At 48 days after stent placement, a chest CT scan shows well expansion of stent and relief of stenosis.](GRP2019-1465301.003){#fig3}

![Stent removal for case 16. (a) Esophagography shows that the contrast agent flows though the covered stent with no leakage 45 days after stent placement. (b, c) The stent was removed under fluoroscopic guidance. (d) After removal of stent, esophagography showed that the contrast agent flowed through the esophagus with no leakage.](GRP2019-1465301.004){#fig4}

![Additional stent placement for restenosis of stent (case 12). (a) Esophagography showed severe restenosis in the proximal end of stent 5 months later. (b) Another covered stent was inserted to relief restenosis. (c, d) A chest CT scan showed well expansion of stent and relief of restenosis.](GRP2019-1465301.005){#fig5}

###### 

Characteristics of the study patients.

  No.   Gender   Age(Y)   Cause                         Course of disease (M)   Duration from surgery to stenosis/leak (M)   Duration of hospitalization (D)   Type of disease             Comorbidities                        Interventional methods    Stent size (mm × mm)
  ----- -------- -------- ----------------------------- ----------------------- -------------------------------------------- --------------------------------- --------------------------- ------------------------------------ ------------------------- ----------------------------------------
  1     Male     70       Gastric carcinoma             9.0                     8.5                                          16                                Anastomotic stenosis        None                                 Stent                     18 × 120
  2     Male     64       Gastric carcinoma             7.0                     3.0                                          6                                 Anastomotic stenosis        None                                 Balloon+stent             20 × 120
  3     Male     72       Gastric carcinoma             5.0                     2.0                                          35                                Anastomotic stenosis        Hypertension                         Balloon+stent             22 × 120; 20 × 100; 20 × 100; 20 × 100
  4     Female   66       Gastric carcinoma             1.0                     1.0                                          32                                Anastomotic stenosis        Hypertension+cardiac insufficiency   Balloon                   None
  5     Male     74       Gastric carcinoma             17.0                    13.0                                         13                                Anastomotic stenosis        None                                 Stent                     20 × 120
  6     Male     56       Esophagogastric carcinoma     12.0                    10.0                                         7                                 Anastomotic stenosis        None                                 Stent                     20 × 100
  7     Male     67       Carcinoma of gastric cardia   3.0                     7.0                                          28                                Anastomotic stenosis        Hypertension                         Stent                     18 × 120
  8     Female   69       Gastric carcinoma             0.7                     0.7                                          40                                Anastomotic stenosis        None                                 Balloon                   None
  9     Male     65       Carcinoma of gastric cardia   24.0                    20.0                                         17                                Anastomotic stenosis        None                                 Stent                     20 × 120
  10    Male     55       Gastric carcinoma             12.0                    11.0                                         22                                Anastomotic stenosis        Diabetes                             Stent                     20 × 100; 20 × 120
  11    Male     58       Gastric carcinoma             7.0                     6.5                                          22                                Anastomotic stenosis        None                                 Stent                     18 × 100
  12    Male     63       Gastric carcinoma             4.0                     1.2                                          16                                Anastomotic stenosis+leak   None                                 Stent+three-tube method   20 × 100; 20 × 100
  13    Female   51       Gastric carcinoma             11.0                    9.0                                          36                                Anastomotic stenosis+leak   None                                 Stent+three-tube method   22 × 80 − 22 × 50 − 22 × 50
  14    Male     44       Gastric carcinoma             4.0                     1.0                                          21                                Anastomotic leak            None                                 Three-tube method         None
  15    Female   72       Gastric carcinoma             0.3                     0.2                                          28                                Anastomotic leak            None                                 Stent+three-tube method   20 × 100
  16    Female   65       Gastric carcinoma             6.0                     0.6                                          75                                Anastomotic leak            Diabetes                             Stent+three-tube method   20 × 140
  17    Female   38       Gastric carcinoma             1.0                     0.3                                          48                                Anastomotic leak            None                                 Three-tube method         None
  18    Male     60       Gastric carcinoma             4.0                     0.1                                          18                                Anastomotic leak            None                                 Three-tube method         None
  19    Male     43       Carcinoma of gastric cardia   3.0                     2.3                                          41                                Anastomotic leak            None                                 Stent+three-tube method   20 × 120
  20    Male     68       Gastric carcinoma             0.7                     0.1                                          13                                Anastomotic leak            None                                 Three-tube method         None
  21    Male     64       Carcinoma of gastric cardia   3.0                     0.2                                          32                                Anastomotic leak            None                                 Stent+three-tube method   20 × 100 − 20 × 40 − 20 × 40
  22    Male     53       Gastric carcinoma             6.0                     1.8                                          19                                Anastomotic leak            None                                 Three-tube method         None
  23    Male     69       Gastric carcinoma             72.0                    0.4                                          53                                Anastomotic leak            Hypertension                         Three-tube method         None
  24    Male     53       Gastric carcinoma             6.0                     0.3                                          32                                Anastomotic leak            None                                 Stent+three-tube method   20 × 100

  Balloon size (mm × mm)      Complications      Adjustment time of stent   Adjustment time of abscess drainage tube   Removal of stent/abscess drainage tube   Retention days of stent   Retention days of abscess drainage tube   Other interventional treatments        Survival time after stent implantation (M)   Death cause
  --------------------------- ------------------ -------------------------- ------------------------------------------ ---------------------------------------- ------------------------- ----------------------------------------- -------------------------------------- -------------------------------------------- ----------------------------------------------
  None                        None               0                          0                                          Yes                                      55                        ---                                       None                                   6.0                                          Died of cancer recurrence
  16 × 40                     None               0                          0                                          No                                       390                       ---                                       None                                   13.0                                         Died of cancer recurrence
  16 × 40; 18 × 40            Stent restenosis   0                          0                                          No                                       368                       ---                                       TACE                                   12.2                                         Died of cancer recurrence
  16 × 40; 18 × 40; 26 × 40   None               0                          0                                          ---                                      ---                       ---                                       None                                   10.2                                         Survive without symptom
  None                        None               0                          0                                          No                                       344                       ---                                       None                                   11.4                                         Survive without symptom
  None                        None               0                          0                                          Lost to follow-up                        Lost to follow-up         ---                                       None                                   ---                                          Lost to follow-up
  None                        None               0                          0                                          No                                       73                        ---                                       TACE                                   2.4                                          Died of cancer recurrence
  18 × 60; 18 × 60; 18 × 60   None               0                          0                                          ---                                      ---                       ---                                       None                                   10.3                                         Survive without symptom
  None                        None               0                          0                                          No                                       120                       ---                                       Lumbar sympathetic block               4.0                                          Died of cancer recurrence
  None                        Stent restenosis   0                          0                                          No                                       71                        ---                                       TACE+intestinal obstruction catheter   2.3                                          Died of cancer recurrence
  None                        None               0                          0                                          No                                       50                        ---                                       None                                   1.6                                          Died of cancer recurrence
  None                        Stent restenosis   0                          0                                          No                                       30                        30                                        None                                   6.8                                          Survive without symptom
  10 × 40; 10 × 40            None               0                          2                                          No                                       ---                       41                                        None                                   1.3                                          Died of cancer recurrence
  None                        None               0                          0                                          Yes                                      ---                       103                                       None                                   46.9                                         Survive without symptom
  None                        None               0                          2                                          Yes                                      17                        17                                        None                                   2.1                                          Died of cancer recurrence
  None                        Stent migration    1                          0                                          Yes                                      45                        45                                        PTCD+stenting in colon                 19.9                                         Died of cancer recurrence
  None                        None               0                          0                                          No                                       ---                       177                                       None                                   5.9                                          Died of cancer recurrence
  None                        None               0                          0                                          Yes                                      ---                       241                                       None                                   52.0                                         Survive without symptom after surgery repair
  None                        Stent migration    1                          2                                          No                                       38                        38                                        None                                   1.2                                          Died of pulmonary infection
  None                        None               0                          0                                          No                                       ---                       7                                         None                                   0.2                                          Died of cancer recurrence
  None                        None               0                          2                                          No                                       87                        87                                        None                                   2.9                                          Died of cancer recurrence
  None                        None               0                          0                                          Yes                                      ---                       212                                       None                                   48.0                                         Survive without symptom
  None                        None               0                          6                                          Yes                                      ---                       111                                       None                                   10.6                                         Survive without symptom
  None                        None               0                          4                                          Yes                                      64                        178                                       None                                   8.1                                          Died of cancer recurrence

Y: years; M: months; D: days; TACE: transcatheter arterial chemoembolization; PTCD: percutaneous transhepatic cholangial drainage.
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